VarmX Revenue and Competitors
Estimated Revenue & Valuation
- VarmX's estimated annual revenue is currently $5.1M per year.
- VarmX's estimated revenue per employee is $155,000
Employee Data
- VarmX has 33 Employees.
- VarmX grew their employee count by 18% last year.
VarmX's People
| Name | Title | Email/Phone |
|---|
VarmX Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $99.4M | 458 | 40% | N/A | N/A |
#2 | $20.6M | 133 | 22% | N/A | N/A |
#3 | $156.1M | 146 | -70% | $145M | N/A |
#4 | $3.5M | 45 | -25% | $150M | N/A |
#5 | $1.6M | 21 | 0% | $459.5M | N/A |
#6 | $67.3M | 310 | 16% | $180.7M | N/A |
#7 | $8.5M | 55 | -2% | N/A | N/A |
#8 | $256.3M | 1025 | 9% | $168.5M | N/A |
#9 | $2.8M | 18 | -33% | N/A | N/A |
#10 | $9.1M | 59 | -9% | N/A | N/A |
What Is VarmX?
VarmX (www.varmx.com) is a young Leiden based biotech company that is focusing on the development of therapies in the field of hemostasis and thrombosis. Originally a spin-off from the Leiden University Medical Center (LUMC), our mission is to develop and manufacture therapeutic proteins to restore hemostasis. Our lead compound, VMX-C001, is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors. The VarmX program has gained significant interest in the investment community and a very successful Series B financing round of €32 mill. was closed in 2020.
keywords:N/A
N/A
Total Funding
33
Number of Employees
$5.1M
Revenue (est)
18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Leiden
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $6.7M | 43 | 10% | N/A |
#2 | $10.7M | 53 | 18% | $101M |
#3 | $13.9M | 57 | 4% | N/A |
#4 | $21.3M | 61 | 20% | N/A |
#5 | $13.7M | 69 | -5% | N/A |